Results 321 to 330 of about 10,512,482 (403)
Gastric and Duodenal Mucosal Healing With Risankizumab in Upper Gastrointestinal Crohn's Disease. [PDF]
Chatto M, Sedano R, Jairath V.
europepmc +1 more source
In this follow‐up of a randomized controlled trial including 1911 primiparous women with a vaginal birth, minor and major second‐degree tears were not associated with pelvic floor dysfunction 1 year postpartum. OASI was associated with colorectal–anal symptoms, whereas episiotomy was associated with vaginal symptoms affecting body image.
Malin Edqvist +9 more
wiley +1 more source
Biomolecular Fingerprint of Crohn's Disease: A Comparative Raman Spectroscopic Study of Blood and Tissue Samples. [PDF]
Ghauri MD +11 more
europepmc +1 more source
The impact of systemic long‐term medications for the development of age‐related macular degeneration
Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä +3 more
wiley +1 more source
Improvement in small-bowel and colonic lesions observed by intestinal ultrasonography in Crohn's disease treated with risankizumab. [PDF]
Miyakawa M +7 more
europepmc +1 more source
The results of a geriatric assessment in older patients with IBD were associated with adverse health outcomes. Frailty, reflected by severe deficits in geriatric assessment, was independently associated with all‐cause and acute hospitalisations in older patients with IBD. ABSTRACT Background Guidelines recommend considering frailty in the management of
Anne B. Fons +10 more
wiley +1 more source
An atypical and diagnostically challenging case of pediatric metastatic Crohn's disease. [PDF]
Belkasmi I +6 more
europepmc +1 more source
Drug‐induced hypersensitivity syndrome followed by exacerbation of Crohn's disease
Pediatric Investigation, EarlyView.
Mei Kamidani +10 more
wiley +1 more source
One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
In a real‐world cohort of patients with highly refractory perianal Crohn's disease, upadacitinib induced clinical remission at 12 months in 26% of patients with fistulizing disease and 25% of those with isolated anal ulcerations. ABSTRACT Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD ...
Nicolas Richard +13 more
wiley +1 more source

